NCT03895515View on ClinicalTrials.gov

Effect of Fiasp® in Type 1 Diabetes Treatment

CompletedOBSERVATIONAL
Enrollment

178

Participants

Timeline

Start Date

January 3, 2020

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Fiasp®

Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.

Trial Locations (1)

141 86

Novo Nordisk Investigational Site, Stockholm

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY